本帖最后由 老马 于 2012-1-13 21:20 编辑
. A9 j7 c1 t1 Y7 q4 t7 u+ P
6 I8 L& o. `9 G! N" B, `3 o, j爱必妥和阿瓦斯丁的比较0 U2 F/ J( z3 G$ P
7 W) H, E3 g$ l( _http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
4 @5 a6 C) G( X8 }! h5 v5 I/ z3 k
9 i' H, k/ g; r h
* R! @* x! q `" P% z7 c3 K$ nhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
1 h4 M+ U& k( ?) k==================================================& E1 g/ i: J0 |' ]% U
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL), I( }4 a6 `! Z9 B# T
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
( k' Y6 Q( ^8 h f; t5 N# C7 z+ QResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
# Z# q$ L. ^9 j0 _" f
|